14 studies found for:    weill | Open Studies | "Liver Diseases"
Show Display Options
Rank Status Study
1 Recruiting Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
2 Unknown  Effect of Large Volume Paracentesis on Fatigue in Cirrhosis
Conditions: Ascites;   Fatigue;   Cirrhosis
Intervention:
3 Unknown  The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
4 Not yet recruiting Safety Study of Gene Transfer Vector to Treat alpha1-antitrypsin Deficiency
Condition: alpha1-antitrypsin Deficiency
Intervention: Genetic: AAVrh.10halpha1AT
5 Unknown  Rifaximin Versus Lactulose in Renal Failure
Conditions: Liver Cirrhosis;   Renal Failure
Interventions: Drug: Rifaximin;   Drug: Lactulose
6 Unknown  Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
Conditions: Spontaneous Bacterial Peritonitis;   Cirrhosis
Interventions: Drug: Standard Care;   Drug: Experimental
7 Recruiting Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)
Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: Simtuzumab;   Biological: Placebo
8 Recruiting HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Condition: Hepatitis C
Intervention:
9 Recruiting Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Conditions: Primary Biliary Cirrhosis;   PBC
Interventions: Drug: LUM001;   Drug: Placebo;   Drug: Ursodeoxycholic Acid
10 Recruiting Simtuzumab (GS-6624) in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab 75 mg;   Biological: Simtuzumab 125 mg;   Biological: Placebo
11 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Breast Cancer;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Bladder Cancer
Intervention: Drug: IMMU-132
13 Recruiting Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
14 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D

Indicates status has not been verified in more than two years